HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

PRRT: Defining the paradigm shift to achieve standardization and individualization.

Abstract
Peptide receptor radionuclide therapy is a treatment for inoperable or metastatic neuroendocrine tumors. A key issue is the need to standardize the treatment and develop randomized controlled trials. Standardization would help define the characteristics of response, including progression-free survival; provide homogeneous phase II and III studies; delineate the position of peptide receptor radionuclide therapy in the therapeutic algorithm for neuroendocrine tumors; and establish the basis for approval by the regulatory authorities. Standardization of treatments is the starting point to redefine the treatment paradigm from a one-size-fits-all to a personalized treatment. To delineate the treatment paradigm, treatments should be optimized for efficacy and minimization of long-term toxicity, through dosimetry, and adapted to each individual, including relevant patient characteristics. Although differences in therapy outcomes may be explained by the specific absorbed dose (or biologically effective dose), they may also be related to discrete tumor- and patient-specific features. In this respect, a particular area of investigation is the assessment of genetic elements regulating tumor cell proliferation, especially those involved in the response to cytotoxic therapies.
AuthorsLisa Bodei, Mark Kidd, Richard P Baum, Irvin M Modlin
JournalJournal of nuclear medicine : official publication, Society of Nuclear Medicine (J Nucl Med) Vol. 55 Issue 11 Pg. 1753-6 (Nov 2014) ISSN: 1535-5667 [Electronic] United States
PMID25256058 (Publication Type: Journal Article)
Copyright© 2014 by the Society of Nuclear Medicine and Molecular Imaging, Inc.
Chemical References
  • Radioisotopes
  • Radiopharmaceuticals
  • Receptors, Peptide
  • Octreotide
Topics
  • Bronchial Neoplasms (diagnostic imaging, radiotherapy)
  • Disease-Free Survival
  • Humans
  • Intestinal Neoplasms (diagnostic imaging, radiotherapy)
  • Neuroendocrine Tumors (diagnostic imaging, radiotherapy)
  • Nuclear Medicine (standards)
  • Octreotide (therapeutic use)
  • Pancreatic Neoplasms (diagnostic imaging, radiotherapy)
  • Precision Medicine
  • Radioisotopes (therapeutic use)
  • Radionuclide Imaging
  • Radiopharmaceuticals (therapeutic use)
  • Receptors, Peptide (therapeutic use)
  • Stomach Neoplasms (diagnostic imaging, radiotherapy)
  • Treatment Outcome

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: